Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 1.28 Delayed Data As of Sep 23 |  +0.27 / +26.73%Today’s Change | 0.71 Today|||52-Week Range 1.76 | -1.54% Year-to-Date |
| BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement Sep 23 / TheStreet.com - Paid Partner Content | BioLineRx Begins Trial on BL-8040/ Keytruda Combination Sep 21 / Zacks.com - Paid Partner Content |
| Previous close | 1.01 |
| Today’s open | 1.10 |
| Day’s range | 1.10 - 1.42 |
| Volume | 9,187,109 |
| Average volume (3 months) | 300,762 |
| Market cap | $72.2M |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| INFIInfinity Pharmaceuti... | -0.01 | -0.68% |
| CAPRCapricor Therapeutic... | -0.12 | -3.31% |
| EPIXESSA Pharma Inc | -0.05 | -2.00% |
| LPCNLipocine Inc | +0.06 | +1.57% |
| Next reporting date | November 9, 2016 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | -- |
| Annual profit (last year) | -- |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters --, -- |
